artenimol has been researched along with Lymphoma, T-Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huo, L; Wang, Q; Wu, S; Zhao, C; Zhao, H; Zhao, X | 1 |
| Bauer, KD; Belka, C; Dürig, J; Freier, F; Handrick, R; Jendrossek, V; Ontikatze, T; Rübel, A | 1 |
2 other study(ies) available for artenimol and Lymphoma, T-Cell
| Article | Year |
|---|---|
Mechanisms of Dihydroartemisinin and Dihydroartemisinin/Holotransferrin Cytotoxicity in T-Cell Lymphoma Cells.
Topics: Antineoplastic Agents; Apoptosis; Artemisinins; Cell Cycle; Cell Line, Tumor; Cell Survival; Gene Expression; Humans; Jurkat Cells; Lymphoma, T-Cell; Reactive Oxygen Species; Receptors, Transferrin; RNA, Messenger; Telomerase; Transferrin; Vascular Endothelial Growth Factor A | 2015 |
Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic pathway.
Topics: Apoptosis; Artemisinins; bcl-2 Homologous Antagonist-Killer Protein; Caspases; Cell Line, Tumor; Humans; Jurkat Cells; Lymphoma, T-Cell; Oxidation-Reduction; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Transfection | 2010 |